Ultragenyx Pharmaceutical RARE underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 6 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 2 | 0 | 0 | 0 |
| 2M Ago | 0 | 3 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $92.75, along with a high estimate of $114.00 and a low estimate of $48.00. Marking an increase of 20.14%, the current average surpasses the previous average price target of $77.20.
Exploring Analyst Ratings: An In-Depth Overview
The standing of Ultragenyx Pharmaceutical among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Anupam Rama | JP Morgan | Raises | Overweight | $92.00 | $88.00 |
| Cory Kasimov | JP Morgan | Raises | Overweight | $88.00 | $84.00 |
| Kristen Kluska | Cantor Fitzgerald | Announces | Overweight | $107.00 | - |
| Whitney Ijem | Canaccord Genuity | Raises | Buy | $111.00 | $110.00 |
| Laura Chico | Wedbush | Raises | Neutral | $48.00 | $47.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $114.00 | - |
| Joel Beatty | Baird | Raises | Outperform | $68.00 | $57.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $114.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ultragenyx Pharmaceutical. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ultragenyx Pharmaceutical compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Ultragenyx Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Ultragenyx Pharmaceutical's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Ultragenyx Pharmaceutical analyst ratings.
Discovering Ultragenyx Pharmaceutical: A Closer Look
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Understanding the Numbers: Ultragenyx Pharmaceutical's Finances
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Ultragenyx Pharmaceutical's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 23.27%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ultragenyx Pharmaceutical's net margin excels beyond industry benchmarks, reaching -96.7%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Ultragenyx Pharmaceutical's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -80.22%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Ultragenyx Pharmaceutical's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -9.03%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.16, Ultragenyx Pharmaceutical adopts a prudent financial strategy, indicating a balanced approach to debt management.
Understanding the Relevance of Analyst Ratings
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
